Myotonic Dystrophy
Conditions
Brief summary
This is a Phase 1/Phase 2 open-label single arm, multicenter, and multinational study with SAR446268 for treatment of male and female participants 10 to 55 years old with non-congenital myotonic dystrophy (DM) type 1 (DM1). The purpose of this study is to evaluate the safety and efficacy of SAR446268 in knocking down dystrophia myotonica protein kinase (DMPK) messenger ribonucleic acid (mRNA) levels and improving neuromuscular function in DM1 participants receiving a single intravenous (IV) administration of SAR446268. The study consists of a dose escalation part (Part A) during which single ascending doses of SAR446268 will be evaluated in 3 distinct cohorts and an optional fourth dose cohort. Once a safe and effective dose is identified, additional participants will be treated in Part B, the dose expansion phase of the study. The study duration will be 112 weeks (approximately 2 years) for each participant in Parts A and B respectively and includes an optional pre-screening period, approximately 8-week screening phase and a 104-week follow-up period post-SAR446268 administration.
Detailed description
Each participant meeting the eligibility criteria for each of the study parts will receive a single dose administration of SAR446268.
Interventions
BIOLOGICALSAR446268
Pharmaceutical form: Solution for infusion; Route of administration: IV infusion
Sponsors
Sanofi
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
10 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
Participants are eligible to be included in the study only if all of the following criteria apply: * For Part A, participants must be 18 to 55 years of age inclusive, at the time of signing the informed consent. * For Part B, participants must be as follows: * 10 to 17 years of age inclusive, at the time of signing the informed consent or, * 18 to 55 years of age inclusive, at the time of signing the informed consent. * Participants with non-congenital onset DM1 * Participants presenting with signs of DM1 including myotonia and muscle weakness, as diagnosed previously by a clinician based on medical history. * Participants with genetic diagnosis of DM1 \[cytosine-thymine-guanine (CTG) repeat length ≥50 in one allele from medical history\] * Participants who can walk independently for at least 10 meters at screening (orthoses and ankle braces allowed).
Exclusion criteria
Participants are excluded from the study if any of the following criteria apply: * Participants with neutralizing antibodies against the AAV.SAN011 capsid * Participants with left ventricular ejection fraction \<50% * Participants with liver or biliary disease defined as having at least one of the following: * ALT \>3 x ULN and AST \>3 x ULN * Alkaline phosphatase \>3 x ULN * Total bilirubin \>1.5 x ULN (unless has a genetically confirmed diagnosis of Gilbert's syndrome) * Direct bilirubin ≥1.5 x ULN * Participants with International normalized ratio \>1.5 * Participants with renal disease defined as: • Serum creatinine \>1.5 x ULN and/or estimated glomerular filtration rate \<60 mL/min/1.73 m2 as determined by Chronic Kidney Disease Epidemiology Collaboration (2021) for those age ≥18 years and Bedside Schwartz Equation for those \<18 years * Participants with chronic respiratory insufficiency and on long term/hull-time ventilatory assistance requiring at least 6 hours per day for at least 21 consecutive days. * Participants with contraindication to corticosteroid or with conditions that could worsen in the presence of corticosteroids, as determined by the Investigator. * Participants with active hepatitis B or C infection; HBsAg (+), or HCV RNA (+), or current antiviral therapy for either. * Participants with HBcAb (+) who are not amenable for prophylactic anti-HBV therapy or pre-emptive therapy guided by serial HBV DNA monitoring during the corticosteroids therapy. * Participants at high risk for tuberculosis reactivation during the corticosteroids therapy as determined by the Investigator. * Participants with a known HIV infection * Participants with serious intercurrent illness that, in the opinion of the Investigator, would preclude participation in the study or potentially decrease survival. * Participants with recent history of or current drug or alcohol abuse in the past 12 months prior to screening. * Participants with history of tibialis anterior biopsy within 12 weeks from Day 1 or planning to undergo tibialis anterior biopsies during the duration of this clinical trial. * Participants with significant developmental delay, intellectual disability, or behavioral neuropsychiatric manifestations as determined by the Investigator. * Participants with previous systemic corticosteroids treatment at doses of \>5 mg/day within 15 days of Day 1 * Participants with previous treatment with anti-myotonic medication within 15 days of Day 1 * Participants not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures. * Participants who have been classified as severe cardiac risk by the Investigator. The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part A and Part B: Incidence of treatment-emergent adverse events (TEAEs) following SAR446268 administration | Baseline to Week 52 | Number of TEAEs post-SAR446268 administration |
| Part B: Proportion of participants with at least 40% DMPK mRNA knockdown in muscle biopsy at Weeks 12 and 52 following SAR446268 administration | Weeks 12 and 52 | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Part A: Change in 10-meter walk-run test from baseline to Weeks 26 and 52 following SAR446268 administration | Baseline to Week 26 and 52 | The 10-meter walk-run test is a mobility test that measures how fast a participant can traverse 10 meters with or without assisted devices. |
| Part A: Change in myotonia from baseline to Weeks 26 and 52 following SAR446268 administration as measured by the hand opening time (middle finger) | Baseline to Week 26 and 52 | This test for myotonia measures how quickly a participant can open his/her hand after making a tight fist. |
| Part A: Change in bilateral hand grip test from baseline to Weeks 26 and 52 following SAR446268 administration | Baseline to Week 26 and 52 | This test for strength of the hand muscles measures the maximum force generated by a participant's hand grip using a dynamometer. |
| Part A: Proportion of participants with at least 40% DMPK mRNA knockdown in muscle biopsy at Weeks 12 and 52 following SAR446268 administration | Weeks 12 and 52 | — |
| Part A: Change in DMPK mRNA levels in muscle biopsy from baseline to Weeks 12 and 52 following SAR446268 administration | Baseline to Week 12 and 52 | — |
| Part A: Change in RNA splicing index in muscle biopsy from baseline to Weeks 12 and 52 following SAR446268 administration | Baseline to Week 12 and 52 | — |
| Part A: Assessment of the duration of AAV vector shedding of SAR446268 in sampling of urine, saliva, and semen at 4-week intervals following SAR446268 administration | Baseline, Weeks 4, 8, and 12 | — |
| Part B: Change in 10-meter walk-run test from baseline to Weeks 26 and 52 following SAR446268 administration | Baseline to Week 26 and 52 | The 10-meter walk-run test is a mobility test that measures how fast a participant can traverse 10 meters with or without assisted devices. |
| Part B: Change in myotonia from baseline to Weeks 26 and 52 following SAR446268 administration as measured by the hand opening time (middle finger) | Baseline to Week 26 and 52 | This test for myotonia measures how quickly a participant can open his/her hand after making a tight fist. |
| Part B: Change in bilateral hand grip test from baseline to Weeks 26 and 52 following SAR446268 administration | Baseline to Week 26 and 52 | This test for strength of the hand muscles measures the maximum force generated by a participant's hand grip using a dynamometer. |
| Part B: Change in DMPK mRNA knockdown in muscle biopsy from baseline to Weeks 12 and 52 following SAR446268 administration | Baseline to Week 12 and 52 | — |
| Part B: Change in RNA splicing index in muscle biopsy from baseline to Weeks 12 and 52 following SAR446268 administration | Baseline to Week 12 and 52 | — |
| Part B: Assessment of the duration of AAV shedding of SAR446268 in sampling of urine, saliva, and semen at 4-week intervals following SAR446268 administration | Baseline, Weeks 4, 8, and 12 | — |
Countries
Argentina, Australia, Canada, Israel, United Kingdom, United States
Contacts
CONTACTTrial Transparency email recommended (Toll free for US & Canada)
Outcome results
None listed